Zydus Lifesciences to acquire API Business of Sterling Biotech Limited
Zydus Lifesciences (ZYDUSLIFE) said it has agreed a deal to acquire API Business of Sterling Biotech Limited. The company is valued at about ₹1.23 lakh crore.
What happened
Zydus Lifesciences (ZYDUSLIFE) told the exchanges on 2 November 2026 at 12:46 PM that it has agreed a deal to acquire API Business of Sterling Biotech Limited.
From the filing: "November 2, 2026 Listing Department Code: 532321 BSE LIMITED P J Towers, Dalal Street, Fort, Mumbai-400001 Listing Department Code: Zyduslife NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai-400051 Re.: Update on acquisition of API business Ref.: 1."
Company snapshot
Zydus Lifesciences is a large-cap company in the Healthcare sector, with a market value of about ₹1.23 lakh crore.
The stock last traded at ₹1,234.7, against a 52-week range of ₹835.5–₹1,248.9 (1.1% below the high).
Before this filing the shares had moved +3.8% over the month and +10.5% over three months. Average daily turnover over the last 20 sessions was about ₹166 crore.
Promoters held 75.01% at the end of Q1 FY27. Foreign institutions owned 6.88% and domestic institutions 11.27%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 6,574 | 1,466.8 | 14.58 |
| Q2 FY26 | 6,123 | 1,258.6 | 12.51 |
| Q3 FY26 | 6,865 | 1,042.1 | 10.36 |
| Q4 FY26 | 7,587 | 1,272.5 | 12.65 |
| Q1 FY27 | 8,017 | 939.8 | 9.35 |
What history shows
This is not the company's first m&a disclosure: BCEIE has 2 earlier filings of this kind on record since May 2026.
Across 154 similar disclosures by other Healthcare companies, shares moved +0.7% on average the next day and +0.8% over five days; 58% of them rose the next day.
Market-wide, 2,237 m&a filings with an impact score of 50 or more saw an average next-day move of +0.3%, with 49% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Regulatory approvals, completion of the deal and its effect on revenue and margins.
- 4 November 2026: Board meeting — Financial Results.
In the news
Recent coverage elsewhere (links open the original publisher):
- Zydus Lifesciences Gets USFDA Approval for Hormone Patch
- ZYDUSLIFE Share Price Today - Zydus Life Science on NSE/BSE
- ZYDUSLIFE Outlook for the Week
- Zydus Lifesciences Ltd. Share Price Today - Zydus Lifesciences Ltd. Stock Price Live NSE/BSE
- Zydus Lifesciences gets USFDA nod for menopause treatment drug
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.